Annovis Bio (ANVS) vs Celularity (CELU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Celularity (CELU) has outperformed Annovis Bio (ANVS) over the past year, losing 32.1% versus a loss of 48.5%. Over five years, ANVS leads with a -95.8% price change compared with -98.0% for CELU. Annovis Bio is the larger company by market cap ($49.9 million vs $47.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANVS | CELU |
|---|---|---|
| Share price | $1.17 | $1.46 |
| Market cap | $49.93M | $47.38M |
| 1-day change | -3.31% | -0.68% |
| YTD return | -66.18% | +31.53% |
| 1-year return | -48.46% | -32.09% |
| 5-year return | -95.82% | -97.97% |
| EPS (TTM) | $-1.75 | $-2.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.50 | $2.55 |
| 52-week low | $1.04 | $0.56 |
| Distance from 52-week high | -78.73% | -42.75% |
| Analyst consensus | none | — |
| Avg. price target upside | +797.44% | — |
| Average volume | 884.63K | 3.89M |
| Shares outstanding | 42.68M | 32.45M |
| Employees | 7 | 115 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CELU has outperformed ANVS by 16.4 percentage points over the past year.
About Annovis Bio
ANVS stock →Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Celularity
CELU stock →Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees
ANVS vs CELU FAQ
Which is bigger, Annovis Bio or Celularity?
Annovis Bio (ANVS) is larger, with a market capitalization of $49.93M compared with $47.38M for Celularity (CELU).
Which stock has performed better over the past year, ANVS or CELU?
CELU returned -32.09% over the past 12 months, compared with -48.46% for ANVS (price return, excluding dividends). Past performance does not predict future results.
Are Annovis Bio and Celularity in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.